Are things looking up for Valeant Pharmaceuticals International (VRX)? The outlook for the drug maker’s debt seems to be improving, at least according to Moody’s Investors Services. The ratings firm did not change Valeant’s credit rating (the corporate family ratings is B3 and the senior unsecured notes are at Caa1), but it did lift its […]
Leave a Reply